Last reviewed · How we verify
brimonidine tartrate 0.2%
Brimonidine tartrate 0.2%, marketed by University Health Network, Toronto, is an established drug in the glaucoma treatment market. The key composition patent expires in 2028, providing a significant period of market exclusivity. The primary risk is the lack of recent key trial results to support ongoing efficacy and safety claims.
At a glance
| Generic name | brimonidine tartrate 0.2% |
|---|---|
| Also known as | Alphagan, Allergan, Irvine, CA, ALPHAGAN P, ALPHAGAN (brimonidine tartrate 0.2%) Allergan Pharm. Ltd |
| Sponsor | University Health Network, Toronto |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients (PHASE4)
- Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost (PHASE4)
- To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes (PHASE3)
- Brimonidine for Intraoperative Hemostasis (PHASE4)
- Triplenex (triple Fixed Combination) Use Evaluation in Patients with Glaucoma (PHASE4)
- Optic Nerve Perfusion Following Treatment with Latanoprost Versus Brimionidin Tartrate (EARLY_PHASE1)
- The Effect of Brimonidine (PHASE4)
- Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- brimonidine tartrate 0.2% CI brief — competitive landscape report
- brimonidine tartrate 0.2% updates RSS · CI watch RSS
- University Health Network, Toronto portfolio CI